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NICE ON STATINS
NICE must do better at summarising and
communicating evidence on statins
Ben M Goldacre research fellow in epidemiology
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
Rabar and colleagues’ summary of the National Institute for
Health and Care Excellence (NICE) guideline on statins omits
the key information clinicians need: the number needed to treat
(NNT) with statins in different risk groups, at different levels
of treatment intensity.1 This is not The BMJ’s shortcoming.
NICE advises doctors to discuss this information with their
patients, but it is missing from the NICE guideline itself.
The most attentive reader might find—in row 10 of 32, in table
43, on page 143—that for every 1000 people without
cardiovascular disease taking a statin, overall there would be
seven fewer non-fatal myocardial infarctions. To establish the
time period over which this figure applies, or whether it relates
to the important new 10% 10 year risk population, requires
downloading and reading Appendix C, a separate document.
Table 60 summarises data from a 2013 Cochrane review, which
(arguably) relates to a 15% 10 year risk population, and reports
an NNT of 88 for “total CHD events” over five years. Attentive
readers could deduce that these events must be non-fatal, or
perhaps mixed fatal and non-fatal, because the NNT for all cause
mortality in the same table is higher.
NICE advises doctors to give clear information on the benefits
of statins. This implies that, after scrutinising a 302 page NICE
report to find the numbers above, GPs should then do a literature
search, read and appraise the trial data, synthesise it (at different
risk strata and treatment intensities), then use the appropriate
formulas to create NNT for easy interpretation by patients.
Clinicians might expect NICE—awell resourced national body
with extensive technical expertise—to have done this for them.
Clear summaries of information on benefit and risk are the
bedrock of informed patient choice. They should be our highest
priority,2 not a poor second cousin. A simple table in NICE’s
own summaries—givingNNTswe know, and highlighting those
we don’t—might be a good place to start. I hope others will
have more suggestions.
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